Lumakras (Sotorasib)
- Medicine Name: Lumakras
- Generic Name: Sotorasib
- Dosage Form & Strength: Tablets: 120 mg
- Manufactured By: Amgen Inc.
Lumakras is an inhibitor of the RAS GTPase family used for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have been earlier treated with at least a single prior systemic therapy.
Recommended Dosage: The recommended dosage is 960 mg (8 × lumakras 120 mg tablets) orally once a day until the disease is progressive or unacceptable toxicity occurs. Take dosage persistently each day with or without food. Swallow the tablets whole, without chewing, crushing or splitting.
If a dose of lumakras is missed by more than 6 hours, take the next dose as scheduled the next day. Do not take a couple of doses at the same time to make up for a missed dose. If vomiting occurs after taking this medicine, do not take an additional dose. Take the next dose as scheduled the very next day.
- The sotorasib 120 mg can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis. Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of therapy, every 3 weeks for the first 3 months of treatment, then monthly.
- Sotorasib can cause ILD/pneumonitis that may be fatal. Assess patients for new/worsening pulmonary symptoms indicative of ILD/pneumonitis. Promptly withhold sotorasib therapy in patients with suspected ILD/pneumonitis and permanently discontinue if no other potential causes of ILD/pneumonitis are observed.
- In case adverse reactions occur, a maximum of a couple of dose reductions are permitted. Therapy with lumakras 120mg should be discontinued if patients are not able to tolerate the minimum dose of 240 mg once a day.
- Avoid the coadministration of H2 receptor antagonists and proton pump inhibitors with Sotorasib. In case therapy with an acid-reducing agent cannot be avoided, take Sotorasib 4 hours prior to or 10 hours after administration of a local antacid.
- While taking lumakras dosage women should neither conceive pregnancy nor breastfeed their child for at least 1 week after the final dose.
What documents are required to import LUMAKRAS to India?
LUMAKRAS (sotorasib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation needed to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is LUMAKRAS available in India?
LUMAKRAS (sotorasib tablet) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
On availability of sotorasib in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
LUMAKRAS can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of LUMAKRAS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for sotorasib price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the LUMAKRAS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.